Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to

  Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower
  Rates of Major Bleeding in Patients Compared to Current Standard of Care for
  the Treatment of Acute Venous Thromboembolism

   Phase 3 AMPLIFY Results Published in New England Journal of Medicine and
 Presented as a Late-Breaker at the Congress of the International Society on
                       Thrombosis and Haemostasis Show:

  *Eliquis Was Noninferior to Current Standard of Care for Treatment of Both
    Symptomatic Deep Vein Thrombosis and Pulmonary Embolism Conditions
  *69 Percent Relative Risk Reduction for Major Bleeding in Patients on
    Eliquis Compared to Current Standard of Care

Business Wire

PRINCETON, N.J. and NEW YORK -- June 30, 2013

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today
announced the results of the six month Phase 3 AMPLIFY trial of 5,395 patients
with acute venous thromboembolism (VTE), which includes symptomatic deep vein
thrombosis (DVT) and/or pulmonary embolism (PE). In this trial, Eliquis as a
single-agent achieved the primary efficacy endpoint of noninferiority to
current standard of care (initial parenteral enoxaparin treatment overlapped
with warfarin therapy) in the reduction of the composite endpoint of recurrent
symptomatic VTE or VTE-related death.

Eliquis also met the primary safety endpoint of superiority for major
bleeding, with a 69 percent relative risk reduction (RRR) compared to current
standard of care.

Importantly, AMPLIFY demonstrated comparable results for the primary efficacy
and safety endpoints between patients entering the study with a DVT or a PE.

The findings were published online in New England Journal of Medicine and
announced at the 24th Congress of the International Society on Thrombosis and
Haemostasis (ISTH).

Venous thromboembolism, or VTE, encompasses two serious conditions: deep vein
thrombosis (DVT), a blood clot in a vein, usually in the leg, that partially
or totally blocks the flow of blood; and pulmonary embolism (PE), a blood clot
blocking one or more vessels in the lungs. VTE continues to be a major cause
of morbidity and mortality, with approximately 900,000 patients in the U.S.
and approximately 1 million patients in the EU diagnosed every year. Once a
VTE has occurred, up to 10 percent of people may have a VTE reoccurrence,
which could potentially be fatal.

“The study results showed that apixaban, as a single-agent, has comparable
efficacy with significantly fewer major bleeding events with respect to the
standard of care. These results complement the previously published results
for the AMPLIFY-EXT study,” said Dr. Giancarlo Agnelli, professor of internal
medicine, University of Perugia, Italy; director of the Department of Internal
and Cardiovascular Medicine and Stroke-Unit, University Hospital, Perugia,
Italy; and lead investigator of the study. “Together these studies represent
exciting data in the field of VTE treatment and indicate that apixaban may
offer an important potential alternative in both acute and extended
anticoagulation therapy for VTE patients.”

Based on the results of AMPLIFY, as well as AMPLIFY-EXT, which were published
online on December 8, 2012, in New England Journal of Medicine with
simultaneous presentation during a late-breaker session at the 54th Annual
Meeting of the American Society of Hematology (ASH), Bristol-Myers Squibb and
Pfizer plan to initiate regulatory filings for the initial and long-term
treatment of VTE, as well as for extended prevention of recurrent VTE.

About AMPLIFY

AMPLIFY, (Apixaban for the initial Management of PuLmonary embolIsm and deep
vein thrombosis as First-line therapY), a randomized, double-blind,
multicenter trial, included 5,395 patients with confirmed symptomatic DVT or
PE requiring treatment for six months, and evaluated Eliquis as a single-agent
(10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
compared to current standard of care (initial parenteral enoxaparin treatment
overlapped by warfarin therapy). Approximately one third of patients in the
trial had a PE at the time of enrollment into the study.

The primary efficacy outcome was the composite endpoint of recurrent
symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death. For the
primary efficacy outcome, Eliquis achieved noninferiority to parenteral
enoxaparin plus warfarin in the reduction of recurrent symptomatic VTE or
VTE-related death. The primary efficacy outcome occurred in 59 patients in the
Eliquis group (2.3%) and 71 patients (2.7%) receiving current standard of care
(relative risk 0.84%; 95% CI, 0.60 to 1.18; P<0.0001 for noninferiority).

Eliquis achieved the primary safety endpoint of superiority for major
bleeding. Major bleeding occurred in 0.6% of patients given Eliquis and 1.8%
of those given current standard of care (relative risk, 0.31; 95% CI, 0.17 to
0.55; P<0.0001 for superiority). The composite of major and clinically
relevant nonmajor bleeding occurred in 4.3% and 9.7% of patients in the
Eliquis and current standard of care groups, respectively (relative risk,
0.44; 95% CI, 0.36 to 0.55). Rates of other adverse events were similar in the
two groups.

AMPLIFY demonstrated a comparable efficacy and safety profile between patients
entering the study with a DVT and/or a PE. In patients enrolled with DVT, the
primary efficacy outcome occurred in 38 patients (2.2%) in the apixaban group
and 47 patients (2.7%) in the current standard of care group (relative risk,
0.83; 95% CI, 0.54 to 1.26; risk difference [apixaban minus current standard
of care] -0.5%; 95% CI, -1.5 to 0.6). In patients enrolled with PE, the
primary efficacy outcome occurred in 21 patients (2.3%) in the apixaban group
and 23 patients (2.6%) in the current standard of care group (relative risk
0.90; 95% CI, 0.50 to 1.61; risk difference -0.3%; 95% CI, -1.7 to 1.2).

About Eliquis^®

Eliquis^® (apixaban) is an oral direct Factor Xa inhibitor. By inhibiting
Factor Xa, a key blood clotting protein, Eliquis prevents thrombin generation
and blood clot formation. Eliquis is approved to reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation in the
United States, European Union (which includes 27 member states plus Iceland
and Norway), Japan and a number of other countries around the world. Eliquis 
is approved for prevention of venous thromboembolic events (VTE) in adult
patients who have undergone elective hip or knee replacement surgery in the
European Union (which includes 27 member states plus Iceland and Norway) and a
number of other countries around the world. Eliquis is not approved for this
indication in the U.S.

IMPORTANT SAFETY INFORMATION FOR ELIQUIS

BOXED WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS
ANTICOAGULATION INCREASES RISK OF STROKE.

Discontinuing ELIQUIS places patients at an increased risk of thrombotic
events. An increased rate of stroke was observed following discontinuation of
ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation.
If anticoagulation with ELIQUIS must be discontinued for a reason other than
pathological bleeding, coverage with another anticoagulant should be strongly
considered.

CONTRAINDICATIONS

- Active pathological bleeding

- Severe hypersensitivity reaction to ELIQUIS (apixaban) (i.e., anaphylactic
reactions)

WARNINGS AND PRECAUTIONS

Increased Risk of Stroke with Discontinuation of ELIQUIS: Discontinuing
ELIQUIS in the absence of adequate alternative anticoagulation increases the
risk of thrombotic events. An increased rate of stroke was observed during the
transition from ELIQUIS to warfarin in clinical trials in patients with
nonvalvular atrial fibrillation. If ELIQUIS must be discontinued for a reason
other than pathological bleeding, consider coverage with another
anticoagulant.

Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious,
potentially fatal bleeding. Concomitant use of drugs affecting hemostasis
increases the risk of bleeding including aspirin and other anti-platelet
agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and
NSAIDs. Patients should be made aware of signs or symptoms of blood loss and
instructed to immediately report to an emergency room. Discontinue ELIQUIS in
patients with active pathological hemorrhage. There is no established way to
reverse the anticoagulant effect of apixaban, which can be expected to persist
for about 24 hours after the last dose (i.e., about two half-lives). A
specific antidote for ELIQUIS is not available. Because of high plasma protein
binding, apixaban is not expected to be dialyzable. Protamine sulfate and
vitamin K would not be expected to affect the anticoagulant activity of
apixaban. There is no experience with antifibrinolytic agents (tranexamic
acid, aminocaproic acid) in individuals receiving apixaban. There is neither
scientific rationale for reversal nor experience with systemic hemostatics
(desmopressin and aprotinin) in individuals receiving apixaban. Use of
procoagulant reversal agents such as prothrombin complex concentrate,
activated prothrombin complex concentrate, or recombinant factor VIIa may be
considered but has not been evaluated in clinical studies. Activated charcoal
reduces absorption of apixaban thereby lowering apixaban plasma
concentrations.

Prosthetic Heart Valves: The safety and efficacy of ELIQUIS has not been
studied in patients with prosthetic heart valves and is not recommended in
these patients.

ADVERSE REACTIONS

The most common and most serious adverse reactions reported with ELIQUIS
(apixaban) were related to bleeding.

DISCONTINUATIONS FOR SURGERY AND OTHER INTERVENTIONS

ELIQUIS should be discontinued at least 48 hours prior to elective surgery or
invasive procedures with a moderate or high risk of unacceptable or clinically
significant bleeding. ELIQUIS should be discontinued at least 24 hours prior
to elective surgery or invasive procedures with a low risk of bleeding or
where the bleeding would be noncritical in location and easily controlled.

DRUG INTERACTIONS

Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of CYP3A4 and P-gp
increase exposure to apixaban and increase the risk of bleeding. Decrease the
dose of ELIQUIS to 2.5 mg twice daily when coadministered with drugs that are
strong dual inhibitors of CYP3A4 and P-gp, (e.g., ketoconazole, itraconazole,
ritonavir, or clarithromycin). In patients already taking ELIQUIS at a dose of
2.5 mg twice daily, avoid coadministration with strong dual inhibitors of
CYP3A4 and P-gp.

Strong Dual Inducers of CYP3A4 and P-gp: Inducers of CYP3A4 and P-gp decrease
exposure to apixaban and increase the risk of stroke. Avoid concomitant use of
ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin,
carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease
exposure to apixaban.

Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet
agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the
risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban
in high-risk post-acute coronary syndrome patients treated with aspirin or the
combination of aspirin and clopidogrel, was terminated early due to a higher
rate of bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B

There are no adequate and well-controlled studies of ELIQUIS in pregnant
women. Treatment is likely to increase the risk of hemorrhage during pregnancy
and delivery. ELIQUIS should be used during pregnancy only if the potential
benefit outweighs the potential risk to the mother and fetus.

Please see full Prescribing Information including BOXED WARNING and Medication
Guide available at www.bms.com.

About the Bristol-Myers Squibb/Pfizer Collaboration

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide
collaboration to develop and commercialize Eliquis, an oral anticoagulant
discovered by Bristol-Myers Squibb. This global alliance combines
Bristol-Myers Squibb's long-standing strengths in cardiovascular drug
development and commercialization with Pfizer’s global scale and expertise in
this field.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit http://www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding
product development. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among other risks, there can be
no guarantee that Eliquis will be approved in the EU for the treatment of VTE
or in the U.S. or other markets for the prevention and treatment of VTE. There
is also no guarantee that Eliquis will become a commercially successful
product. Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb's
business, particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2012, in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

PFIZER DISCLOSURE NOTICE:

The information contained in this release is as of June 30, 2013. Pfizer
assumes no obligation to update forward-looking statements contained in this
release as the result of new information or future events or developments.

This release contains forward-looking information about Eliquis (apixaban),
including its potential benefits and the anticipated submission of
applications with regulatory authorities for the initial and long-term
treatment of VTE and for the extended prevention of recurrent VTE (the
“Additional Indications”), that involves substantial risks and uncertainties.
Such risks and uncertainties include, among other things, (i) the
uncertainties inherent in research and development; (ii) whether and when any
applications will be submitted with regulatory authorities for the Additional
Indications; (iii) whether and when any such applications, if submitted, may
be approved by regulatory authorities as well as their decisions regarding
labeling and other matters that could affect the availability or commercial
potential of the Additional Indications; and (iv) competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and in
its reports on Form 10-Q and Form 8-K.

Contact:

Bristol-Myers Squibb
Chrissy Trank (Media)
609-252-3418
christina.trank@bms.com
Ranya Dajani(Investors)
609-252-5330
ranya.dajani@bms.com
Ryan Asay (Investors)
609-252-5020
ryan.asay@bms.com
or
Pfizer Inc.
Jennifer Kokell (Media)
917-741-4254
jennifer.kokell@pfizer.com

Suzanne Harnett (Investors)
212-733-8009
suzanne.harnett@pfizer.com